| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S2213-2600(18)30406-5 |
| P698 | PubMed publication ID | 30416083 |
| P50 | author | Richard Olsson | Q42810536 |
| Eugene R Bleecker | Q65560413 | ||
| P2093 | author name string | Peter Barker | |
| William W Busse | |||
| J Mark FitzGerald | |||
| Gary T Ferguson | |||
| Ubaldo J Martin | |||
| Mitchell Goldman | |||
| BORA study investigators | |||
| Stephanie Sproule | |||
| P2860 | cites work | Global asthma prevalence in adults: findings from the cross-sectional world health survey | Q34201679 |
| The poorly explored impact of uncontrolled asthma | Q34326184 | ||
| Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma | Q34557028 | ||
| Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational study | Q34903683 | ||
| Biologic therapies targeting eosinophils: current status and future prospects | Q35565533 | ||
| Tissue and BAL based biomarkers in asthma | Q36998180 | ||
| The consequences of not having eosinophils. | Q37561562 | ||
| International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma | Q38171268 | ||
| Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial | Q39408906 | ||
| Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial | Q45297326 | ||
| Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies | Q50053497 | ||
| The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies. | Q51345374 | ||
| Reductions in eosinophil biomarkers by benralizumab in patients with asthma. | Q53641303 | ||
| MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function | Q60632052 | ||
| P433 | issue | 1 | |
| P921 | main subject | asthma | Q35869 |
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | 46-59 | |
| P577 | publication date | 2018-11-08 | |
| P1433 | published in | The Lancet. Respiratory medicine | Q27724908 |
| P1476 | title | Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial | |
| P478 | volume | 7 |
| Q90040504 | 2020 Brazilian Thoracic Association recommendations for the management of asthma |
| Q95273637 | COVID-19, asthma, and biologic therapies: What we need to know |
| Q64113098 | Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors? |
| Q94446722 | Eosinophil Responses During COVID-19 Infections and Coronavirus Vaccination |
| Q92536062 | Interleukin-5 in the Pathophysiology of Severe Asthma |
| Q89481425 | Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma |
| Q90330860 | NSAID-ERD Syndrome: the New Hope from Prevention, Early Diagnosis, and New Therapeutic Targets |
| Q92696109 | New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic |
| Q104567544 | Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial |
| Q91657123 | Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis |
| Q89670380 | Severe Asthma and Biological Therapy: When, Which, and for Whom |
| Q93081762 | Severe Eosinophilic Asthma |
| Q92485478 | Targeting eosinophils: severe asthma and beyond |
| Q92068607 | Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma |
Search more.